Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Cell culture studies demonstrate that GLP3 exhibits differential potency across its three target receptors: it is approximately 8.9-fold more potent at the human GIP receptor (EC50: 0.0643 nM) compared to the endogenous GIP ligand, while showing reduced potency at GLP-1 receptors (0.4-fold, EC50: 0.775 nM) and glucagon receptors (0.3-fold, EC50: 5.79 nM) relative to their native hormones[3]
Otherwise, serious adverse events were reported in ~6% of participants and were evenly distributed across tirzepatide and placebo groups
Remember, these medications are not a magic bullet but simply a tool to help you sustain common sense lifestyle changes
Stanzione, M
